Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group.

Kim SJ, Moon JH, Kim H, Kim JS, Hwang YY, Intragumtornchai T, Issaragrisil S, Kwak JY, Lee JJ, Won JH, Reksodiputro AH, Lim ST, Cheng AL, Kim WS, Kwong YL.

Leuk Lymphoma. 2012 Aug;53(8):1515-24. doi: 10.3109/10428194.2012.659735. Epub 2012 Mar 1.

PMID:
22273250
2.

Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.

Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Kim SH, Kim HJ, Cho SG, Eom KS, Lee JW, Min WS, Shin WS, Kim CC.

Transpl Infect Dis. 2009 Oct;11(5):413-23. doi: 10.1111/j.1399-3062.2009.00414.x. Epub 2009 Aug 24.

PMID:
19708893
3.

Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.

Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR.

Clin Infect Dis. 2006 Jul 1;43(1):16-24. Epub 2006 May 17.

PMID:
16758413
4.

Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.

Lush RJ, Haynes AP, Byrne J, Cull GM, Carter GI, Pagliuca A, Parker JE, Mufti G, Mahendra P, Craddock CF, Lui Yin JA, Garg M, Prentice HG, Potter MN, Russell NH.

Cytotherapy. 2001;3(3):203-10.

PMID:
12171727
5.

Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab.

Song WK, Min YH, Kim YR, Lee SC.

Ophthalmology. 2008 Oct;115(10):1766-70. doi: 10.1016/j.ophtha.2008.04.015. Epub 2008 Jun 17.

PMID:
18562004
6.

Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation.

Hill QA, Hill A, Collyns TA, Pearce RM, Cook G.

Bone Marrow Transplant. 2008 Apr;41(8):749-51. doi: 10.1038/sj.bmt.1705974. Epub 2008 Jan 14. No abstract available.

PMID:
18195685
7.

Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation.

Medd P, Littlewood S, Danby R, Malladi R, Clifford R, Wareham D, Jeffery K, Ferry B, Roberts D, Peniket A, Littlewood T.

Bone Marrow Transplant. 2011 Jul;46(7):993-9. doi: 10.1038/bmt.2010.244. Epub 2010 Oct 18.

PMID:
20956951
8.

Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath).

Myers GD, Krance RA, Weiss H, Kuehnle I, Demmler G, Heslop HE, Bollard CM.

Bone Marrow Transplant. 2005 Dec;36(11):1001-8.

PMID:
16184180
9.

Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.

Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R.

Bone Marrow Transplant. 2000 May;25(10):1021-8.

10.

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

Hale G, Slavin S, Goldman JM, Mackinnon S, Giralt S, Waldmann H.

Bone Marrow Transplant. 2002 Dec;30(12):797-804. Review.

11.

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.

Peggs KS, Sureda A, Qian W, Caballero D, Hunter A, Urbano-Ispizua A, Cavet J, Ribera JM, Parker A, Canales M, Mahendra P, Garcia-Conde J, Milligan D, Sanz G, Thomson K, Arranz R, Goldstone AH, Alvarez I, Linch DC, Sierra J, Mackinnon S; UK and Spanish Collaborative Groups..

Br J Haematol. 2007 Oct;139(1):70-80.

PMID:
17854309
12.

Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.

Vallejo C, Ríos E, de la Serna J, Jarque I, Ferrá C, Sánchez-Godoy P, Solano C, de la Cámara R, Rosell AI, Varela R, García MD, González-Barca E, López J, Pérez E, Ferrer S, Casado LF, Vázquez L, Villalón L, García-Marco JA.

Expert Rev Hematol. 2011 Feb;4(1):9-16. doi: 10.1586/ehm.10.77.

PMID:
21322774
13.

Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.

Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J, Shutt KA, Shapiro R, Thai N, Abu-Elmagd K, McCurry KR, Marcos A, Paterson DL.

Clin Infect Dis. 2007 Jan 15;44(2):204-12. Epub 2006 Dec 13.

PMID:
17173218
14.

Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.

Kline J, Pollyea DA, Stock W, Artz A, Rich E, Godley L, Zimmerman T, Thompson K, Pursell K, Larson RA, van Besien K.

Bone Marrow Transplant. 2006 Feb;37(3):307-10.

PMID:
16400339
15.

The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.

Delgado J, Pillai S, Benjamin R, Caballero D, Martino R, Nathwani A, Lovell R, Thomson K, Perez-Simon JA, Sureda A, Kottaridis P, Vazquez L, Peggs K, Sierra J, Milligan D, Mackinnon S.

Biol Blood Marrow Transplant. 2008 Nov;14(11):1288-97. doi: 10.1016/j.bbmt.2008.09.001.

16.

Fungal infections in transplant recipients receiving alemtuzumab.

Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, Dunn DL, Humar A.

Transplant Proc. 2005 Mar;37(2):934-6.

PMID:
15848579
17.

Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.

George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.

Transpl Infect Dis. 2010 Aug 1;12(4):322-9. doi: 10.1111/j.1399-3062.2010.00504.x. Epub 2010 May 11.

PMID:
20487414
18.

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.

Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, Morris E, Orchard K, Rule S, Russell N, Craddock C, Marks DI; Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT)..

Biol Blood Marrow Transplant. 2010 Oct;16(10):1419-27. doi: 10.1016/j.bbmt.2010.04.006. Epub 2010 Apr 24.

19.
20.

Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.

Tan BH, Chlebicka NL, Low JG, Chong TY, Chan KP, Goh YT.

Transpl Infect Dis. 2008 Oct;10(5):325-32. doi: 10.1111/j.1399-3062.2008.00325.x. Epub 2008 Jul 8.

PMID:
18627578

Supplemental Content

Support Center